A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

Saved in:
Bibliographic Details
Title: A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Authors: Previs RA; Duke University Medical Center, Durham, NC, USA. Electronic address: rebecca.previs@gmail.com., Bevis KS; University of Alabama at Birmingham, Birmingham, AL, USA., Huh W; University of Alabama at Birmingham, Birmingham, AL, USA., Tillmanns T; West Clinic and University of Tennessee Health Science Center, Memphis, TN, USA., Perry L; Stevenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA., Moore K; Stevenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA., Chapman J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Stanford Women's Cancer Center, Stanford Hospital and Clinics, Palo Alto, CA, USA., McClung C; Stanford Women's Cancer Center, Stanford Hospital and Clinics, Palo Alto, CA, USA., Kiet T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Java J; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, USA., Chan J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Secord AA; Duke University Medical Center, Durham, NC, USA.
Source: Gynecologic oncology [Gynecol Oncol] 2014 Mar; Vol. 132 (3), pp. 531-6. Date of Electronic Publication: 2014 Jan 25.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1095-6859
DOI:10.1016/j.ygyno.2014.01.036